{"organizations": [], "uuid": "d84f80f4a8893c2a0201b5fdd5dd32719e185edc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-marinus-pharmaceuticals-reports-qu/brief-marinus-pharmaceuticals-reports-quarterly-loss-per-share-0-15-idUSASC09YYA", "country": "US", "domain_rank": 408, "title": "Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.022, "site_type": "news", "published": "2018-05-02T19:40:00.000+03:00", "replies_count": 0, "uuid": "d84f80f4a8893c2a0201b5fdd5dd32719e185edc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-marinus-pharmaceuticals-reports-qu/brief-marinus-pharmaceuticals-reports-quarterly-loss-per-share-0-15-idUSASC09YYA", "ord_in_thread": 0, "title": "Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "marinus pharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "marinus pharmaceuticals inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 2 (Reuters) - Marinus Pharmaceuticals Inc:\n* MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS\n* MARINUS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.15\n* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017\n* MARINUS PHARMACEUTICALS -BELIEVES THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS, AS OF MARCH 31, 2018, ARE ADEQUATE TO FUND ITS OPERATIONS INTO 2020 ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-02T19:40:00.000+03:00", "crawled": "2018-05-02T14:57:53.029+03:00", "highlightTitle": ""}